| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cocaine-Related Disorders | 28 | 2023 | 201 | 7.460 |
Why?
|
| Opioid-Related Disorders | 17 | 2022 | 264 | 4.750 |
Why?
|
| Cocaine | 15 | 2023 | 205 | 3.780 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 9 | 2022 | 45 | 2.990 |
Why?
|
| Tryptophan Hydroxylase | 19 | 2019 | 33 | 2.650 |
Why?
|
| Receptors, Opioid, mu | 11 | 2018 | 30 | 2.450 |
Why?
|
| Disulfiram | 7 | 2021 | 34 | 2.210 |
Why?
|
| DNA Methylation | 11 | 2021 | 1053 | 2.110 |
Why?
|
| Heroin Dependence | 9 | 2012 | 56 | 2.110 |
Why?
|
| Buprenorphine | 3 | 2022 | 95 | 1.810 |
Why?
|
| Substance-Related Disorders | 9 | 2024 | 462 | 1.680 |
Why?
|
| Polymorphism, Genetic | 20 | 2022 | 819 | 1.680 |
Why?
|
| Genotype | 32 | 2023 | 2569 | 1.560 |
Why?
|
| Receptors, Opioid | 6 | 2016 | 14 | 1.440 |
Why?
|
| Neonatal Abstinence Syndrome | 4 | 2018 | 17 | 1.310 |
Why?
|
| Genetic Variation | 12 | 2017 | 1505 | 1.280 |
Why?
|
| Pharmacogenetics | 8 | 2022 | 185 | 1.250 |
Why?
|
| Receptors, Opioid, delta | 3 | 2021 | 12 | 1.240 |
Why?
|
| Behavior, Addictive | 3 | 2022 | 59 | 1.200 |
Why?
|
| Dopamine beta-Hydroxylase | 6 | 2018 | 28 | 1.200 |
Why?
|
| Impulsive Behavior | 7 | 2024 | 145 | 1.180 |
Why?
|
| Methadone | 11 | 2021 | 125 | 1.170 |
Why?
|
| Protein Precursors | 9 | 2022 | 150 | 1.080 |
Why?
|
| Genetic Predisposition to Disease | 14 | 2024 | 3175 | 1.070 |
Why?
|
| Suicidal Ideation | 5 | 2024 | 222 | 1.040 |
Why?
|
| Receptors, Opioid, kappa | 5 | 2015 | 23 | 1.010 |
Why?
|
| Alcoholism | 10 | 2021 | 230 | 0.950 |
Why?
|
| Epigenesis, Genetic | 8 | 2021 | 703 | 0.950 |
Why?
|
| Brain-Derived Neurotrophic Factor | 5 | 2024 | 115 | 0.910 |
Why?
|
| Promoter Regions, Genetic | 7 | 2023 | 1339 | 0.900 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 3 | 2020 | 17 | 0.900 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2014 | 119 | 0.820 |
Why?
|
| Doxazosin | 2 | 2020 | 20 | 0.810 |
Why?
|
| Serotonin | 8 | 2015 | 212 | 0.800 |
Why?
|
| Alleles | 17 | 2023 | 1615 | 0.790 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2019 | 34 | 0.750 |
Why?
|
| Catechol O-Methyltransferase | 5 | 2016 | 25 | 0.750 |
Why?
|
| Polymorphism, Single Nucleotide | 17 | 2016 | 2654 | 0.730 |
Why?
|
| Narcotic Antagonists | 2 | 2022 | 109 | 0.730 |
Why?
|
| Adult | 42 | 2024 | 29459 | 0.680 |
Why?
|
| Genome-Wide Association Study | 6 | 2024 | 1694 | 0.680 |
Why?
|
| Humans | 101 | 2024 | 125110 | 0.680 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2018 | 623 | 0.680 |
Why?
|
| Cannabinoids | 3 | 2019 | 31 | 0.660 |
Why?
|
| Hospitals, Psychiatric | 2 | 2019 | 68 | 0.640 |
Why?
|
| Acetaldehyde Dehydrogenase Inhibitors | 1 | 2019 | 5 | 0.640 |
Why?
|
| Minisatellite Repeats | 1 | 2019 | 42 | 0.630 |
Why?
|
| Male | 60 | 2024 | 61443 | 0.620 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2018 | 9 | 0.610 |
Why?
|
| Vaccines | 2 | 2013 | 366 | 0.600 |
Why?
|
| Schizophrenia | 4 | 2024 | 312 | 0.590 |
Why?
|
| Bipolar Disorder | 5 | 2024 | 356 | 0.580 |
Why?
|
| Apolipoprotein E4 | 1 | 2018 | 45 | 0.580 |
Why?
|
| Naloxone | 1 | 2018 | 48 | 0.580 |
Why?
|
| Cannabis | 1 | 2018 | 41 | 0.580 |
Why?
|
| Brain Injuries, Traumatic | 2 | 2018 | 276 | 0.560 |
Why?
|
| Headache | 1 | 2018 | 106 | 0.560 |
Why?
|
| Lymphocytes | 3 | 2010 | 408 | 0.560 |
Why?
|
| Apolipoproteins E | 1 | 2018 | 192 | 0.560 |
Why?
|
| Genetic Markers | 5 | 2019 | 605 | 0.550 |
Why?
|
| Female | 55 | 2024 | 66704 | 0.540 |
Why?
|
| Dopamine | 2 | 2015 | 279 | 0.530 |
Why?
|
| Inpatients | 3 | 2022 | 497 | 0.530 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2014 | 43 | 0.530 |
Why?
|
| Anxiety | 5 | 2024 | 943 | 0.530 |
Why?
|
| Hippocampus | 3 | 2020 | 824 | 0.490 |
Why?
|
| Enkephalins | 5 | 2022 | 18 | 0.470 |
Why?
|
| Mental Disorders | 2 | 2019 | 827 | 0.450 |
Why?
|
| Veterans | 4 | 2024 | 1715 | 0.450 |
Why?
|
| Body Size | 1 | 2014 | 55 | 0.440 |
Why?
|
| Maternal Behavior | 1 | 2014 | 66 | 0.430 |
Why?
|
| Introns | 6 | 2015 | 300 | 0.420 |
Why?
|
| Cholera Toxin | 2 | 2013 | 49 | 0.420 |
Why?
|
| Sex Characteristics | 2 | 2016 | 314 | 0.410 |
Why?
|
| Depression | 1 | 2021 | 1232 | 0.410 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2013 | 37 | 0.410 |
Why?
|
| Middle Aged | 23 | 2024 | 26676 | 0.400 |
Why?
|
| Social Adjustment | 1 | 2013 | 80 | 0.400 |
Why?
|
| Heroin | 1 | 2012 | 19 | 0.400 |
Why?
|
| Resilience, Psychological | 1 | 2013 | 67 | 0.380 |
Why?
|
| Suicide, Attempted | 6 | 2024 | 132 | 0.380 |
Why?
|
| Fear | 1 | 2013 | 199 | 0.370 |
Why?
|
| Cerebellum | 1 | 2014 | 441 | 0.340 |
Why?
|
| Naltrexone | 2 | 2022 | 70 | 0.330 |
Why?
|
| Suicide | 4 | 2024 | 179 | 0.320 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 2 | 2020 | 19 | 0.310 |
Why?
|
| Brain | 9 | 2020 | 3014 | 0.310 |
Why?
|
| Analgesics, Opioid | 5 | 2018 | 409 | 0.310 |
Why?
|
| Linkage Disequilibrium | 8 | 2014 | 308 | 0.300 |
Why?
|
| RNA, Messenger | 11 | 2014 | 2814 | 0.300 |
Why?
|
| Double-Blind Method | 6 | 2020 | 1605 | 0.300 |
Why?
|
| Stress, Psychological | 1 | 2013 | 550 | 0.290 |
Why?
|
| Marijuana Abuse | 2 | 2019 | 49 | 0.290 |
Why?
|
| Treatment Outcome | 9 | 2021 | 12272 | 0.290 |
Why?
|
| Precision Medicine | 3 | 2016 | 321 | 0.280 |
Why?
|
| Brain Injuries | 1 | 2013 | 705 | 0.280 |
Why?
|
| Otitis Externa | 1 | 2006 | 5 | 0.270 |
Why?
|
| Psychotic Disorders | 2 | 2019 | 138 | 0.270 |
Why?
|
| Gene Frequency | 7 | 2008 | 728 | 0.270 |
Why?
|
| Rats | 16 | 2022 | 3728 | 0.260 |
Why?
|
| Medical Informatics | 1 | 2007 | 109 | 0.240 |
Why?
|
| Young Adult | 8 | 2024 | 9056 | 0.240 |
Why?
|
| Codeine | 1 | 2005 | 22 | 0.230 |
Why?
|
| Demography | 2 | 2017 | 239 | 0.230 |
Why?
|
| Vaping | 1 | 2024 | 30 | 0.230 |
Why?
|
| Social Responsibility | 2 | 2014 | 80 | 0.230 |
Why?
|
| Research Report | 2 | 2014 | 75 | 0.220 |
Why?
|
| Trans-Activators | 1 | 2008 | 801 | 0.220 |
Why?
|
| Advisory Committees | 2 | 2014 | 153 | 0.220 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2024 | 44 | 0.220 |
Why?
|
| Ethanol | 2 | 2022 | 162 | 0.210 |
Why?
|
| Sex Factors | 3 | 2019 | 1275 | 0.210 |
Why?
|
| Administration, Intravenous | 2 | 2021 | 143 | 0.210 |
Why?
|
| Haplotypes | 5 | 2010 | 520 | 0.200 |
Why?
|
| Length of Stay | 3 | 2019 | 1306 | 0.200 |
Why?
|
| Paternal Exposure | 1 | 2022 | 10 | 0.200 |
Why?
|
| American Heart Association | 2 | 2014 | 322 | 0.200 |
Why?
|
| Base Sequence | 11 | 2010 | 3109 | 0.200 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2022 | 4 | 0.190 |
Why?
|
| Semen | 1 | 2022 | 77 | 0.190 |
Why?
|
| Patient Discharge | 2 | 2024 | 492 | 0.190 |
Why?
|
| Nerve Tissue Proteins | 2 | 2017 | 1130 | 0.190 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2014 | 1243 | 0.190 |
Why?
|
| Delayed-Action Preparations | 1 | 2022 | 109 | 0.190 |
Why?
|
| Injections, Intramuscular | 1 | 2022 | 194 | 0.190 |
Why?
|
| Isoenzymes | 2 | 2008 | 232 | 0.190 |
Why?
|
| Nuclear Proteins | 1 | 2008 | 1284 | 0.180 |
Why?
|
| Animals | 32 | 2022 | 34304 | 0.180 |
Why?
|
| Synechococcus | 1 | 2021 | 3 | 0.180 |
Why?
|
| Islets of Langerhans | 10 | 1988 | 174 | 0.180 |
Why?
|
| Physician-Patient Relations | 2 | 2014 | 427 | 0.180 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2010 | 1033 | 0.170 |
Why?
|
| Twins, Monozygotic | 1 | 2001 | 117 | 0.170 |
Why?
|
| Depressive Disorder, Major | 2 | 2016 | 402 | 0.160 |
Why?
|
| Molecular Sequence Data | 9 | 2008 | 3898 | 0.160 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2019 | 9 | 0.160 |
Why?
|
| Hydroxyindoleacetic Acid | 4 | 1997 | 29 | 0.160 |
Why?
|
| Cardiology | 2 | 2014 | 507 | 0.160 |
Why?
|
| Models, Genetic | 2 | 2019 | 761 | 0.160 |
Why?
|
| Cohort Studies | 4 | 2024 | 4821 | 0.150 |
Why?
|
| Case-Control Studies | 4 | 2015 | 3310 | 0.150 |
Why?
|
| Polyunsaturated Alkamides | 1 | 2018 | 28 | 0.150 |
Why?
|
| Apolipoprotein E3 | 1 | 2018 | 5 | 0.150 |
Why?
|
| Arachidonic Acids | 1 | 2018 | 29 | 0.150 |
Why?
|
| Amidohydrolases | 1 | 2018 | 23 | 0.150 |
Why?
|
| Absenteeism | 1 | 2018 | 20 | 0.150 |
Why?
|
| Endocannabinoids | 1 | 2018 | 37 | 0.150 |
Why?
|
| Seasons | 2 | 1999 | 312 | 0.150 |
Why?
|
| Norepinephrine | 2 | 2018 | 171 | 0.150 |
Why?
|
| Membrane Transport Proteins | 1 | 1999 | 174 | 0.140 |
Why?
|
| DNA, Single-Stranded | 2 | 1995 | 74 | 0.140 |
Why?
|
| Pilot Projects | 2 | 2020 | 1395 | 0.140 |
Why?
|
| Hallucinogens | 1 | 2018 | 43 | 0.140 |
Why?
|
| Affect | 1 | 2018 | 156 | 0.140 |
Why?
|
| Prefrontal Cortex | 2 | 2021 | 184 | 0.140 |
Why?
|
| Habenula | 1 | 2017 | 42 | 0.130 |
Why?
|
| Nucleic Acid Heteroduplexes | 1 | 1996 | 17 | 0.130 |
Why?
|
| Membrane Glycoproteins | 1 | 1999 | 413 | 0.130 |
Why?
|
| Infant, Newborn | 4 | 2018 | 8275 | 0.130 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2017 | 143 | 0.130 |
Why?
|
| Receptors, Nicotinic | 1 | 2017 | 155 | 0.130 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 1995 | 70 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1237 | 0.130 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2016 | 13 | 0.130 |
Why?
|
| Heterozygote | 1 | 2018 | 672 | 0.130 |
Why?
|
| Vitellogenins | 3 | 1990 | 11 | 0.130 |
Why?
|
| Connectome | 1 | 2017 | 104 | 0.120 |
Why?
|
| Serotonin Agents | 1 | 2015 | 14 | 0.120 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2018 | 229 | 0.120 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 1995 | 42 | 0.120 |
Why?
|
| Pain | 1 | 2018 | 447 | 0.120 |
Why?
|
| DNA, Complementary | 3 | 2005 | 463 | 0.120 |
Why?
|
| Transcription, Genetic | 5 | 2010 | 1708 | 0.120 |
Why?
|
| Nucleic Acid Conformation | 1 | 1995 | 186 | 0.120 |
Why?
|
| Thiones | 1 | 2014 | 8 | 0.120 |
Why?
|
| Microarray Analysis | 1 | 2015 | 236 | 0.110 |
Why?
|
| Carbidopa | 1 | 2014 | 18 | 0.110 |
Why?
|
| Limbic System | 1 | 2014 | 22 | 0.110 |
Why?
|
| Receptors, Serotonin | 4 | 2008 | 42 | 0.110 |
Why?
|
| Individuality | 1 | 2014 | 33 | 0.110 |
Why?
|
| Levodopa | 1 | 2014 | 91 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 1999 | 1035 | 0.110 |
Why?
|
| Memory Disorders | 1 | 2016 | 229 | 0.110 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 1999 | 796 | 0.110 |
Why?
|
| Receptor, Serotonin, 5-HT2C | 1 | 2014 | 31 | 0.110 |
Why?
|
| Mothers | 1 | 2016 | 356 | 0.110 |
Why?
|
| Amputation, Traumatic | 1 | 2013 | 10 | 0.110 |
Why?
|
| Alcohol Deterrents | 1 | 2013 | 12 | 0.110 |
Why?
|
| DNA-Directed RNA Polymerases | 2 | 2021 | 121 | 0.110 |
Why?
|
| Frontal Lobe | 1 | 2014 | 116 | 0.110 |
Why?
|
| Genetic Association Studies | 2 | 2014 | 780 | 0.100 |
Why?
|
| Mother-Child Relations | 1 | 2014 | 78 | 0.100 |
Why?
|
| Reward | 1 | 2014 | 111 | 0.100 |
Why?
|
| Imidazoles | 1 | 2014 | 206 | 0.100 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2013 | 73 | 0.100 |
Why?
|
| Software | 2 | 2008 | 687 | 0.100 |
Why?
|
| Afghan Campaign 2001- | 1 | 2013 | 117 | 0.100 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2013 | 126 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1992 | 87 | 0.100 |
Why?
|
| Computer Simulation | 1 | 2015 | 650 | 0.100 |
Why?
|
| Social Perception | 1 | 2013 | 55 | 0.100 |
Why?
|
| Exons | 3 | 2008 | 802 | 0.100 |
Why?
|
| Psychiatry | 1 | 2016 | 263 | 0.100 |
Why?
|
| Transfection | 4 | 2010 | 1077 | 0.100 |
Why?
|
| Genetic Carrier Screening | 1 | 2012 | 69 | 0.100 |
Why?
|
| Adolescent | 6 | 2024 | 19414 | 0.100 |
Why?
|
| Attention | 1 | 2014 | 201 | 0.100 |
Why?
|
| Risk Factors | 4 | 2024 | 10278 | 0.100 |
Why?
|
| Gait | 1 | 2013 | 144 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 2906 | 0.100 |
Why?
|
| Insulin | 6 | 1988 | 1203 | 0.100 |
Why?
|
| Self Concept | 1 | 2013 | 153 | 0.090 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2012 | 121 | 0.090 |
Why?
|
| Hirsutism | 3 | 1985 | 21 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 4 | 1997 | 1592 | 0.090 |
Why?
|
| Infant | 2 | 2018 | 12610 | 0.090 |
Why?
|
| Chromosome Mapping | 2 | 2010 | 1086 | 0.090 |
Why?
|
| Drug Therapy, Combination | 3 | 2012 | 1158 | 0.090 |
Why?
|
| Behavior, Animal | 2 | 2013 | 490 | 0.090 |
Why?
|
| Walking | 1 | 2013 | 216 | 0.090 |
Why?
|
| Hormones | 2 | 1990 | 186 | 0.090 |
Why?
|
| CpG Islands | 2 | 2011 | 330 | 0.090 |
Why?
|
| Social Support | 1 | 2013 | 340 | 0.090 |
Why?
|
| Biomarkers | 2 | 2019 | 3105 | 0.090 |
Why?
|
| Tandem Repeat Sequences | 1 | 2010 | 36 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 3402 | 0.090 |
Why?
|
| Base Pairing | 1 | 2010 | 42 | 0.090 |
Why?
|
| Animals, Newborn | 1 | 2014 | 1019 | 0.090 |
Why?
|
| Dinucleoside Phosphates | 1 | 2010 | 11 | 0.080 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2014 | 1006 | 0.080 |
Why?
|
| United States | 5 | 2024 | 10884 | 0.080 |
Why?
|
| Escherichia coli | 3 | 2021 | 968 | 0.080 |
Why?
|
| Lymphocyte Count | 1 | 2010 | 118 | 0.080 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2010 | 117 | 0.080 |
Why?
|
| Phenotype | 3 | 2021 | 4270 | 0.080 |
Why?
|
| Comorbidity | 2 | 2012 | 1526 | 0.080 |
Why?
|
| Receptors, Estrogen | 2 | 1990 | 794 | 0.080 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1989 | 79 | 0.080 |
Why?
|
| Violence | 3 | 1995 | 114 | 0.080 |
Why?
|
| Cognition | 1 | 2014 | 724 | 0.080 |
Why?
|
| Finland | 3 | 1998 | 42 | 0.080 |
Why?
|
| Cyproterone | 2 | 1985 | 4 | 0.080 |
Why?
|
| Ethinyl Estradiol | 2 | 1985 | 10 | 0.080 |
Why?
|
| Gene Expression Regulation | 6 | 1996 | 2527 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2012 | 815 | 0.080 |
Why?
|
| Cyclic AMP | 2 | 2007 | 247 | 0.080 |
Why?
|
| Polymorphism, Restriction Fragment Length | 3 | 1997 | 148 | 0.070 |
Why?
|
| Age Factors | 2 | 2014 | 2815 | 0.070 |
Why?
|
| Cryptochromes | 1 | 2008 | 7 | 0.070 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2008 | 33 | 0.070 |
Why?
|
| Flavoproteins | 1 | 2008 | 16 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 1114 | 0.070 |
Why?
|
| Reference Values | 2 | 2008 | 719 | 0.070 |
Why?
|
| Pregnancy | 2 | 2018 | 7221 | 0.070 |
Why?
|
| Androgen Antagonists | 2 | 1985 | 120 | 0.070 |
Why?
|
| Oocytes | 1 | 1990 | 299 | 0.070 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2008 | 45 | 0.070 |
Why?
|
| Genes | 3 | 1988 | 447 | 0.070 |
Why?
|
| Estradiol | 1 | 1990 | 528 | 0.070 |
Why?
|
| Gene Amplification | 1 | 2008 | 236 | 0.070 |
Why?
|
| Benzethonium | 1 | 2006 | 1 | 0.070 |
Why?
|
| Chromosomes, Human, X | 1 | 2008 | 158 | 0.070 |
Why?
|
| Computer Graphics | 1 | 2007 | 38 | 0.070 |
Why?
|
| Database Management Systems | 1 | 2007 | 31 | 0.070 |
Why?
|
| Exudates and Transudates | 1 | 2006 | 21 | 0.070 |
Why?
|
| Acetic Acid | 1 | 2006 | 18 | 0.070 |
Why?
|
| Propylene Glycols | 1 | 2006 | 19 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 3675 | 0.070 |
Why?
|
| T-Phages | 1 | 1986 | 3 | 0.070 |
Why?
|
| RNA Caps | 1 | 1986 | 31 | 0.070 |
Why?
|
| Administration, Topical | 1 | 2006 | 138 | 0.070 |
Why?
|
| Androgens | 2 | 1985 | 279 | 0.060 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 2 | 1998 | 32 | 0.060 |
Why?
|
| Plasmids | 2 | 1986 | 513 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2006 | 262 | 0.060 |
Why?
|
| Steroids | 1 | 2006 | 202 | 0.060 |
Why?
|
| Self Administration | 2 | 2021 | 43 | 0.060 |
Why?
|
| Analgesics | 1 | 2006 | 127 | 0.060 |
Why?
|
| Drug Hypersensitivity | 1 | 2006 | 96 | 0.060 |
Why?
|
| Amphetamines | 1 | 2005 | 10 | 0.060 |
Why?
|
| Risk-Taking | 1 | 2005 | 96 | 0.060 |
Why?
|
| Proinsulin | 2 | 1986 | 12 | 0.060 |
Why?
|
| Hydrocortisone | 1 | 1985 | 216 | 0.060 |
Why?
|
| Antisocial Personality Disorder | 2 | 1996 | 63 | 0.060 |
Why?
|
| Antipsychotic Agents | 2 | 2019 | 374 | 0.060 |
Why?
|
| Molecular Biology | 1 | 2005 | 80 | 0.060 |
Why?
|
| Neuroimaging | 2 | 2020 | 344 | 0.060 |
Why?
|
| Genetic Linkage | 2 | 1998 | 455 | 0.060 |
Why?
|
| Tobacco Products | 1 | 2024 | 61 | 0.060 |
Why?
|
| Databases, Genetic | 1 | 2007 | 475 | 0.060 |
Why?
|
| Gene Expression | 2 | 2008 | 1554 | 0.060 |
Why?
|
| Central Nervous System Stimulants | 1 | 2005 | 127 | 0.060 |
Why?
|
| Genetics, Population | 1 | 2005 | 187 | 0.060 |
Why?
|
| Internet | 1 | 2007 | 375 | 0.050 |
Why?
|
| Cigarette Smoking | 1 | 2024 | 59 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2006 | 257 | 0.050 |
Why?
|
| Organ Size | 2 | 2016 | 442 | 0.050 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2024 | 53 | 0.050 |
Why?
|
| Galactosidases | 1 | 1983 | 7 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2005 | 256 | 0.050 |
Why?
|
| Sweden | 2 | 2001 | 35 | 0.050 |
Why?
|
| Brain Chemistry | 1 | 2004 | 126 | 0.050 |
Why?
|
| beta-Galactosidase | 1 | 1983 | 147 | 0.050 |
Why?
|
| Self-Injurious Behavior | 1 | 2024 | 64 | 0.050 |
Why?
|
| Multifactorial Inheritance | 1 | 2024 | 139 | 0.050 |
Why?
|
| Glucose | 3 | 1988 | 876 | 0.050 |
Why?
|
| Genes, Bacterial | 1 | 1983 | 210 | 0.050 |
Why?
|
| Research Design | 1 | 2007 | 693 | 0.050 |
Why?
|
| Aftercare | 1 | 2024 | 146 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2008 | 516 | 0.050 |
Why?
|
| Tobacco Use | 1 | 2022 | 25 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 1762 | 0.050 |
Why?
|
| Cell Separation | 2 | 1982 | 230 | 0.050 |
Why?
|
| Personality | 2 | 2005 | 104 | 0.050 |
Why?
|
| Computational Biology | 1 | 2007 | 819 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2007 | 1172 | 0.050 |
Why?
|
| Amino Acid Substitution | 2 | 2016 | 398 | 0.050 |
Why?
|
| Cell Line | 5 | 2010 | 2756 | 0.050 |
Why?
|
| Conditioning, Operant | 1 | 2021 | 17 | 0.050 |
Why?
|
| Nucleus Accumbens | 1 | 2021 | 53 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2008 | 1016 | 0.050 |
Why?
|
| Cloning, Molecular | 3 | 2010 | 898 | 0.050 |
Why?
|
| Heart Rate | 2 | 2015 | 582 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 1893 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 1982 | 802 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2021 | 380 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 3600 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2022 | 344 | 0.040 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2021 | 157 | 0.040 |
Why?
|
| Regression Analysis | 2 | 1998 | 776 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 2061 | 0.040 |
Why?
|
| Xenopus laevis | 2 | 1990 | 127 | 0.040 |
Why?
|
| Seasonal Affective Disorder | 1 | 1999 | 3 | 0.040 |
Why?
|
| Anorexia Nervosa | 1 | 1999 | 24 | 0.040 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2018 | 28 | 0.040 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2018 | 34 | 0.040 |
Why?
|
| Eukaryotic Cells | 2 | 1989 | 32 | 0.040 |
Why?
|
| Family | 2 | 1998 | 562 | 0.040 |
Why?
|
| Prisoners | 1 | 1998 | 35 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 1996 | 1078 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2008 | 2603 | 0.040 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 1997 | 5 | 0.040 |
Why?
|
| Serotonin Receptor Agonists | 1 | 1997 | 23 | 0.030 |
Why?
|
| Schizophrenic Psychology | 1 | 2018 | 82 | 0.030 |
Why?
|
| Corpus Striatum | 1 | 2017 | 93 | 0.030 |
Why?
|
| Biogenic Monoamines | 1 | 1997 | 3 | 0.030 |
Why?
|
| Clinical Trials as Topic | 3 | 2014 | 1095 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2024 | 721 | 0.030 |
Why?
|
| Avoidance Learning | 1 | 2017 | 59 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 164 | 0.030 |
Why?
|
| RNA Precursors | 1 | 1997 | 67 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 1685 | 0.030 |
Why?
|
| Pharmacogenomic Variants | 1 | 2016 | 35 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1996 | 309 | 0.030 |
Why?
|
| Texas | 1 | 2024 | 3571 | 0.030 |
Why?
|
| Aged | 2 | 2024 | 19656 | 0.030 |
Why?
|
| Aggression | 1 | 1998 | 221 | 0.030 |
Why?
|
| RNA Splicing | 1 | 1997 | 230 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 1996 | 143 | 0.030 |
Why?
|
| Anisotropy | 1 | 2015 | 124 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1995 | 78 | 0.030 |
Why?
|
| Mice | 8 | 2005 | 17740 | 0.030 |
Why?
|
| Thermodynamics | 1 | 1995 | 145 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2015 | 164 | 0.030 |
Why?
|
| Stroop Test | 1 | 2014 | 7 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2015 | 284 | 0.030 |
Why?
|
| Serotonin 5-HT2 Receptor Agonists | 1 | 2014 | 14 | 0.030 |
Why?
|
| Appetitive Behavior | 1 | 2014 | 14 | 0.030 |
Why?
|
| Diacylglycerol Kinase | 1 | 2014 | 15 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 1997 | 454 | 0.030 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2014 | 81 | 0.030 |
Why?
|
| Calcium Channels, L-Type | 1 | 2014 | 53 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2015 | 240 | 0.030 |
Why?
|
| Cues | 1 | 2014 | 93 | 0.030 |
Why?
|
| Artificial Limbs | 1 | 2013 | 7 | 0.030 |
Why?
|
| Amputees | 1 | 2013 | 8 | 0.030 |
Why?
|
| Azepines | 1 | 2014 | 64 | 0.030 |
Why?
|
| DNA Primers | 2 | 2010 | 657 | 0.030 |
Why?
|
| Kinetics | 2 | 1987 | 1330 | 0.030 |
Why?
|
| Opiate Substitution Treatment | 1 | 2013 | 25 | 0.030 |
Why?
|
| Ankyrins | 1 | 2014 | 95 | 0.030 |
Why?
|
| Valine | 2 | 2008 | 110 | 0.030 |
Why?
|
| Cricetinae | 2 | 2007 | 422 | 0.030 |
Why?
|
| Indoles | 1 | 2014 | 191 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 586 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1995 | 587 | 0.020 |
Why?
|
| Leg | 1 | 2013 | 154 | 0.020 |
Why?
|
| Amino Acids | 1 | 1995 | 668 | 0.020 |
Why?
|
| Choice Behavior | 1 | 2012 | 132 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 317 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 1253 | 0.020 |
Why?
|
| Models, Biological | 2 | 2005 | 1465 | 0.020 |
Why?
|
| Nucleic Acid Denaturation | 1 | 1990 | 28 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2019 | 16339 | 0.020 |
Why?
|
| Poly A | 1 | 1990 | 59 | 0.020 |
Why?
|
| Receptor, Melanocortin, Type 2 | 1 | 2010 | 1 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 1071 | 0.020 |
Why?
|
| Receptor, Serotonin, 5-HT1B | 1 | 2010 | 5 | 0.020 |
Why?
|
| Epigenomics | 1 | 2011 | 176 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1990 | 190 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2011 | 325 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 1996 | 2878 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2015 | 1351 | 0.020 |
Why?
|
| Chromatography, Thin Layer | 1 | 1989 | 46 | 0.020 |
Why?
|
| Pedigree | 1 | 1992 | 1610 | 0.020 |
Why?
|
| Cyproterone Acetate | 2 | 1985 | 8 | 0.020 |
Why?
|
| Cell Membrane | 3 | 2007 | 464 | 0.020 |
Why?
|
| Receptors, Serotonin, 5-HT3 | 1 | 2008 | 7 | 0.020 |
Why?
|
| Galanin | 1 | 2008 | 6 | 0.020 |
Why?
|
| Alcohol-Related Disorders | 1 | 2008 | 35 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 1990 | 581 | 0.020 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 1980 | 102 | 0.020 |
Why?
|
| Pituitary-Adrenal System | 1 | 2008 | 37 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2013 | 765 | 0.020 |
Why?
|
| Algorithms | 1 | 1995 | 1630 | 0.020 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2008 | 64 | 0.020 |
Why?
|
| Narcotics | 1 | 2008 | 62 | 0.020 |
Why?
|
| Methionine | 1 | 2008 | 102 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1988 | 70 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2010 | 738 | 0.020 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 2007 | 2 | 0.020 |
Why?
|
| Colforsin | 1 | 2007 | 51 | 0.020 |
Why?
|
| Rats, Inbred Strains | 3 | 1982 | 233 | 0.020 |
Why?
|
| Mesocricetus | 1 | 2007 | 72 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2007 | 192 | 0.020 |
Why?
|
| Exercise | 1 | 2013 | 814 | 0.020 |
Why?
|
| Multigene Family | 1 | 2008 | 301 | 0.020 |
Why?
|
| Amino Acid Sequence | 4 | 1996 | 2717 | 0.020 |
Why?
|
| Peptide Biosynthesis | 1 | 1986 | 19 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 810 | 0.020 |
Why?
|
| Estrogens | 1 | 1989 | 503 | 0.020 |
Why?
|
| Dexamethasone | 1 | 1988 | 270 | 0.020 |
Why?
|
| Bucladesine | 1 | 1985 | 20 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2007 | 358 | 0.020 |
Why?
|
| Homovanillic Acid | 2 | 1997 | 25 | 0.020 |
Why?
|
| Somatostatin | 2 | 1982 | 69 | 0.010 |
Why?
|
| New York | 1 | 2004 | 68 | 0.010 |
Why?
|
| Glucagon | 2 | 1982 | 184 | 0.010 |
Why?
|
| Calcium | 2 | 1988 | 1105 | 0.010 |
Why?
|
| 5' Untranslated Regions | 1 | 2004 | 58 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2004 | 291 | 0.010 |
Why?
|
| Gene Library | 1 | 2005 | 218 | 0.010 |
Why?
|
| DNA Restriction Enzymes | 1 | 1983 | 122 | 0.010 |
Why?
|
| Operon | 1 | 1983 | 50 | 0.010 |
Why?
|
| Protein Biosynthesis | 2 | 1983 | 666 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2007 | 887 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1983 | 394 | 0.010 |
Why?
|
| DNA | 1 | 2008 | 1621 | 0.010 |
Why?
|
| Simian virus 40 | 1 | 1983 | 199 | 0.010 |
Why?
|
| Exocrine Glands | 1 | 1982 | 8 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 874 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 1981 | 51 | 0.010 |
Why?
|
| Phosphorylation | 1 | 1985 | 1640 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1982 | 396 | 0.010 |
Why?
|
| Chickens | 1 | 1982 | 636 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1982 | 221 | 0.010 |
Why?
|
| Patient Selection | 1 | 2004 | 694 | 0.010 |
Why?
|
| Scattering, Radiation | 1 | 1981 | 53 | 0.010 |
Why?
|
| Kidney | 1 | 2007 | 1360 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1981 | 238 | 0.010 |
Why?
|
| Cations | 1 | 1980 | 39 | 0.010 |
Why?
|
| Fenfluramine | 1 | 1998 | 11 | 0.010 |
Why?
|
| Prolactin | 1 | 1998 | 113 | 0.010 |
Why?
|
| Receptors, Serotonin, 5-HT1 | 1 | 1997 | 6 | 0.010 |
Why?
|
| CHO Cells | 1 | 1997 | 169 | 0.010 |
Why?
|
| Peptides | 1 | 1980 | 812 | 0.010 |
Why?
|
| Methoxyhydroxyphenylglycol | 1 | 1997 | 35 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 1996 | 11 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1996 | 121 | 0.010 |
Why?
|
| p-Chloroamphetamine | 1 | 1995 | 3 | 0.010 |
Why?
|
| Serotonin Antagonists | 1 | 1995 | 24 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1996 | 216 | 0.010 |
Why?
|
| Isoleucine | 1 | 1995 | 29 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1996 | 658 | 0.010 |
Why?
|
| Down-Regulation | 1 | 1997 | 692 | 0.010 |
Why?
|
| Serine | 1 | 1995 | 175 | 0.010 |
Why?
|
| Glycine | 1 | 1995 | 168 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1995 | 1017 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 1995 | 274 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1996 | 635 | 0.010 |
Why?
|
| In Vitro Techniques | 2 | 1988 | 971 | 0.010 |
Why?
|
| Motor Activity | 1 | 1995 | 521 | 0.010 |
Why?
|
| Mutation | 2 | 1996 | 5906 | 0.010 |
Why?
|
| Molecular Weight | 2 | 1981 | 387 | 0.010 |
Why?
|
| Mice, Inbred Strains | 2 | 1981 | 309 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 2 | 1980 | 97 | 0.000 |
Why?
|
| Hospitalization | 1 | 1997 | 1784 | 0.000 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1996 | 1985 | 0.000 |
Why?
|
| Receptor, Insulin | 1 | 1986 | 68 | 0.000 |
Why?
|
| Amanitins | 1 | 1985 | 6 | 0.000 |
Why?
|
| Dactinomycin | 1 | 1985 | 66 | 0.000 |
Why?
|
| H-2 Antigens | 1 | 1981 | 24 | 0.000 |
Why?
|
| Rats, Inbred Lew | 1 | 1981 | 68 | 0.000 |
Why?
|
| Light | 1 | 1981 | 175 | 0.000 |
Why?
|
| Antibodies | 1 | 1981 | 374 | 0.000 |
Why?
|
| Organophosphorus Compounds | 1 | 1980 | 23 | 0.000 |
Why?
|
| Mice, Obese | 1 | 1980 | 71 | 0.000 |
Why?
|
| Peptide Hydrolases | 1 | 1980 | 145 | 0.000 |
Why?
|
| Adenosine Triphosphate | 1 | 1980 | 280 | 0.000 |
Why?
|
| Potassium | 1 | 1980 | 284 | 0.000 |
Why?
|
| Cell Fractionation | 1 | 1978 | 36 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1978 | 443 | 0.000 |
Why?
|
| Adenosine Triphosphatases | 1 | 1978 | 202 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1981 | 1026 | 0.000 |
Why?
|
| Proteins | 1 | 1980 | 1040 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1981 | 3044 | 0.000 |
Why?
|